Panaxea is proud to announce that it takes place in this consortium with 11 other parties, like the Middlesex University and Amsterdam’s Emma Children’s Hospital. CRADL (which stands for Continuous Regional Analysis Device for neonate Lung) will show how EID can provide new cost effective, easy to use, respiratory management tools and clinical protocols to reduce deaths and disability in infants and children with respiratory failure.

Take a look on the project website for more information about the goals of CRADL, or to see the other participating parties.